We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VMC:NYSEVulcan Materials Company (Holding Company) Analysis

Data as of 2026-03-10 - not real-time

$274.33

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Vulcan Materials (VMC) is trading around $274, well below its 20‑day SMA of $306 and 50‑day SMA of $303, indicating a price lag in an overall bullish trend (SMA200 at $289). The RSI sits near 31, placing the stock in oversold territory, while the MACD remains bearish with the line below the signal. Recent Q4 results showed a modest 3.2% revenue increase but missed earnings expectations, creating short‑term pressure. Support sits near $267 and the current price comfortably remains above it, yet the 52‑week high of $331 serves as a distant resistance.
Valuation metrics are stretched: a trailing P/E of 34 and forward P/E of 25 contrast sharply with a DCF‑derived fair value of roughly $13, signaling significant overvaluation. The company generates solid cash flow, maintains a low payout ratio (~24%), and carries a debt‑to‑equity of ~58%, supporting dividend sustainability. Investor sentiment is bullish (Fear/Greed index at “Extreme Greed”), but the combination of high valuation, earnings miss, and moderate growth suggests caution.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term moving averages
  • Oversold RSI indicating potential bounce
  • Recent earnings miss raising near‑term uncertainty

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Fundamental cash‑flow strength supporting dividend
  • Analyst consensus remains “Buy” with 23 coverage
  • Potential upside if price recovers toward median target around $331

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Sustained demand for construction aggregates
  • High valuation limits upside potential
  • Stable dividend with low payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth3.20%
Profit Margin13.56%
P/E Ratio33.7
ROE12.97%
ROA5.78%
Debt/Equity57.78
P/B Ratio4.2
Op. Cash Flow$1.8B
Free Cash Flow$409.0M

Technical Analysis

TrendBullish
RSI31.3
Support$266.81
Resistance$331.09
MA 20$306.43
MA 50$303.23
MA 200$288.84
MACDBearish
VolumeStable
Fear & Greed Index77.95

Valuation

Fair Value$13.18
Target Price$326.87
Upside/Downside19.15%
GradeOvervalued
TypeGrowth
Dividend Yield0.76%

Risk Assessment

Beta0.65
Volatility37.97%
Sector RiskMedium
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.